{"schema":"hottub-news/prospects/v1","item":{"id":"n_cxeaggv2mk6jarsf5lpq","title":"Biocon's Pertuzumab Gets Marketing Authorization in EU, First Biosimilar Approved Under New Tailored Clinical Approach","title_en":null,"url":"https://www.equitybulls.com/news/379202/biocon-s-pertuzumab-gets-marketing-authorization-eu-first","outlet":"equitybulls.com","published":"2026-11-18T06:23:00Z","sponsored":false,"page":"https://hottub.news/articles/n_cxeaggv2mk6jarsf5lpq"},"prospects":[{"name":"Equity Bulls","kind":"person","role":"reporter","company":"equitybulls.com","website":"https://equitybulls.com/","source":"https://www.equitybulls.com/news/379202/biocon-s-pertuzumab-gets-marketing-authorization-eu-first","note":"Wrote: Biocon's Pertuzumab Gets Marketing Authorization in EU, First Biosimilar Approved Under New Tailored Clinical Approach","reason":"Reporter at equitybulls.com; wrote “Biocon's Pertuzumab Gets Marketing Authorization in EU, First Biosimilar Approved Under New Tailored Clinical Approach” on 2026-11-18","group":"Reporters","add_url":"https://crm.joinhottub.com/relationships/add#name=Equity%20Bulls&company=equitybulls.com&website=https%3A%2F%2Fequitybulls.com%2F&source=https%3A%2F%2Fwww.equitybulls.com%2Fnews%2F379202%2Fbiocon-s-pertuzumab-gets-marketing-authorization-eu-first&note=Wrote%3A%20Biocon%27s%20Pertuzumab%20Gets%20Marketing%20Authorization%20in%20EU%2C%20First%20Biosimilar%20Approved%20Under%20New%20Tailored%20Clinical%20Approach","propose":{"name":"Equity Bulls","kind":"person","reason":"Reporter at equitybulls.com; wrote “Biocon's Pertuzumab Gets Marketing Authorization in EU, First Biosimilar Approved Under New Tailored Clinical Approach” on 2026-11-18","requestId":"news:n_cxeaggv2mk6jarsf5lpq:Reporter:dafe4ee8:e9200793","company":"equitybulls.com","website":"https://equitybulls.com/","sourceUrl":"https://www.equitybulls.com/news/379202/biocon-s-pertuzumab-gets-marketing-authorization-eu-first"}},{"name":"equitybulls.com","kind":"organization","role":"outlet","website":"https://equitybulls.com/","source":"https://www.equitybulls.com/news/379202/biocon-s-pertuzumab-gets-marketing-authorization-eu-first","note":"Published: Biocon's Pertuzumab Gets Marketing Authorization in EU, First Biosimilar Approved Under New Tailored Clinical Approach (2026-11-18)","reason":"Published “Biocon's Pertuzumab Gets Marketing Authorization in EU, First Biosimilar Approved Under New Tailored Clinical Approach” on 2026-11-18","group":"Outlet","add_url":"https://crm.joinhottub.com/relationships/add#name=equitybulls.com&kind=organization&website=https%3A%2F%2Fequitybulls.com%2F&source=https%3A%2F%2Fwww.equitybulls.com%2Fnews%2F379202%2Fbiocon-s-pertuzumab-gets-marketing-authorization-eu-first&note=Published%3A%20Biocon%27s%20Pertuzumab%20Gets%20Marketing%20Authorization%20in%20EU%2C%20First%20Biosimilar%20Approved%20Under%20New%20Tailored%20Clinical%20Approach%20%282026-11-18%29","propose":{"name":"equitybulls.com","kind":"organization","reason":"Published “Biocon's Pertuzumab Gets Marketing Authorization in EU, First Biosimilar Approved Under New Tailored Clinical Approach” on 2026-11-18","requestId":"news:n_cxeaggv2mk6jarsf5lpq:Outlet:5036a8cf:1e4f91d1","website":"https://equitybulls.com/","sourceUrl":"https://www.equitybulls.com/news/379202/biocon-s-pertuzumab-gets-marketing-authorization-eu-first"}}],"someone_else":{"source":"https://www.equitybulls.com/news/379202/biocon-s-pertuzumab-gets-marketing-authorization-eu-first","note":"In the news: Biocon's Pertuzumab Gets Marketing Authorization in EU, First Biosimilar Approved Under New Tailored Clinical Approach (equitybulls.com, 2026-11-18)"},"crm":{"name":"CRM by Hottub","add":"Open add_url in a browser: CRM by Hottub's add form, filled in. Nothing is saved until the person presses Add.","mcp":"https://crm.joinhottub.com/api/crm/mcp","tool":"propose_relationship","propose":"If you're connected to CRM by Hottub's MCP server with proposal access, call propose_relationship with `propose` as its arguments. An owner approves it before anything is added. Keep the arguments as given: retries reuse requestId."}}